Improving Vaccine Assessment Pathways and Decision Making in the Polish Immunization Program

Author:

Czech Marcin12ORCID,Augustynowicz Ewa3,Byliniak Michał4,Jackowska Teresa5,Konstanty Mikołaj67ORCID,Kuchar Ernest8ORCID,Mastalerz-Migas Agnieszka910,Niewada Maciej11,Nitsch-Osuch Aneta12ORCID,Paradowska-Stankiewicz Iwona3ORCID,Pinkas Jarosław13ORCID,Szulc Jakub14,Wysocki Jacek15

Affiliation:

1. Department of Pharmacoeconomics, Institute of Mother and Child, 01-211 Warsaw, Poland

2. Business School, Warsaw University of Technology, 02-008 Warsaw, Poland

3. Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health-National Institute of Hygiene-National Research Institute, 00-791 Warsaw, Poland

4. INFARMA, The Employers’ Union of Innovative Pharmaceutical Companies, 02-670 Warsaw, Poland

5. Department of Pediatrics, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland

6. Silesian Pharmaceutical Chamber, 40-637 Katowice, Poland

7. Polish Pharmaceutical Chamber, 02-390 Warsaw, Poland

8. Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, 02-091 Warsaw, Poland

9. Polish Society of Family Medicine, 51-141 Wrocław, Poland

10. Department of Family Medicine, Wrocław Medical University, 50-367 Wrocław, Poland

11. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland

12. Department of Social Medicine and Public Health, Medical University of Warsaw, 02-091 Warsaw, Poland

13. School of Public Health, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland

14. Alab Laboratories, 00-739 Warsaw, Poland

15. Department of Preventive Medicine, Poznań University of Medical Sciences, 60-781 Poznań, Poland

Abstract

This study examines the vaccine market access pathway in Poland to evaluate its efficiency and propose recommendations for its improvement. The research spans a comprehensive analysis of the vaccine assessment process, ranging from pre-registration to sustainability, encompassing critical components such as national immunization technical advisory groups (NITAGs), health technology assessments, resource evaluations, and decision making. This investigation utilizes a multi-phase approach. Initial desk research aimed to collect accumulated evidence about each step of the vaccine access pathway. This constituted the background for an expert panel discussion (n = 13) and a final online questionnaire (n = 12), evaluating the timeframes, inclusiveness, transparency, and consistency of the elements of the process. Poland is a late adopter of new vaccines. The country faces budget constraints and lacks a formalized framework for the inclusion of vaccines into the national immunization program. Notably, NITAGs play a crucial role, yet their limited resources and dependence on public health stakeholders diminish their impact. A formal and well-supported advisory body may become a foundation for decision-making processes. The health technology assessment conducted by the national agency is recognized for its timeliness and transparency, though the absence of fiscal analyses in vaccine assessments is identified as a gap that limits the understanding of the value of vaccinations. Resources are key drivers of decision making, and recent changes in legislation offer increased flexibility in financing vaccines. Challenges in the procurement process include a limited consideration of non-acquisition costs and an increased absence of a documented general strategy for immunization program development in Poland, pointing to a need for strategic planning. In conclusion, this study recommends the establishment of a robust NITAG with enhanced resources, incorporating fiscal analyses, transparent resource allocation, and strategic planning for immunization program development. Addressing these recommendations is crucial for optimizing Poland’s vaccine market access pathway, ensuring timely and efficient population-wide vaccine access.

Funder

INFARMA

Employers’ Union of Innovative Pharmaceutical Companies

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3